Circulating tumour cells (CTCs) reflect the aggressiveness of tumours and they are the prognostic markers in metastatic breast, prostate and colorectal cancers. An accurate prognosis provides prediction of the probable course and outcome of cancer. Many research studies have been made to develop assays that accurately detect CTC. Through monitoring CTC levels, doctors and physicians can obtain more information about a cancer patient’s prognosis.
Dr. Gleave is the executive director of the Vancouver Prostate Centre (VPC) and a distinguished professor in the Department of Urologic Sciences at UBC. Hosted by the Vancouver Coastal Health Research Institute and the University of British Columbia, VPC is Canada’s leading prostate cancer research institution as well as an internationally recognized Centre of Excellence.
Multiple Sclerosis (MS) is the leading cause of neurological disability in the world1. Canadians have one of the highest rates of MS and three Canadians are diagnosed with MS every day2. The disease randomly attacks the myelin coating of nerves in the brain, optic nerves and spinal cord causing permanent scaring. MS patients are in need for treatments that can make a difference in their quality of life — this is the driving force in health and medical research.
